# Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas

> **NCT00453427** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 20 (actual)

## Conditions studied

- Peripheral T-cell Lymphomas

## Interventions

- **DRUG:** Alemtuzumab (Campath-1H)

## Key facts

- **NCT ID:** NCT00453427
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2013-06
- **Final completion:** 2015-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453427, "Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00453427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*